VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q57661894 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000330.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q57661894‏
024 ‎‡a 0000-0002-3156-3418‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q57661894‏
100 0 ‎‡a Philip Robinson‏ ‎‡9 eo‏ ‎‡9 co‏ ‎‡9 io‏ ‎‡9 af‏ ‎‡9 vmf‏ ‎‡9 vi‏ ‎‡9 ca‏ ‎‡9 it‏ ‎‡9 an‏ ‎‡9 eu‏ ‎‡9 cy‏ ‎‡9 gd‏ ‎‡9 pt-br‏ ‎‡9 ga‏ ‎‡9 zu‏ ‎‡9 cs‏ ‎‡9 et‏ ‎‡9 gl‏ ‎‡9 ie‏ ‎‡9 id‏ ‎‡9 es‏ ‎‡9 en-gb‏ ‎‡9 lb‏ ‎‡9 wa‏ ‎‡9 nn‏ ‎‡9 min‏ ‎‡9 nb‏ ‎‡9 pms‏ ‎‡9 nap‏ ‎‡9 lij‏ ‎‡9 li‏ ‎‡9 wo‏ ‎‡9 lt‏ ‎‡9 frp‏ ‎‡9 sw‏ ‎‡9 nds-nl‏ ‎‡9 rm‏ ‎‡9 ro‏ ‎‡9 ia‏ ‎‡9 sr-el‏ ‎‡9 pcd‏ ‎‡9 vec‏ ‎‡9 kab‏ ‎‡9 sco‏ ‎‡9 nrm‏ ‎‡9 hr‏ ‎‡9 bm‏ ‎‡9 de‏ ‎‡9 hu‏ ‎‡9 da‏ ‎‡9 fr‏ ‎‡9 prg‏ ‎‡9 br‏ ‎‡9 fi‏ ‎‡9 vls‏ ‎‡9 vo‏ ‎‡9 kg‏ ‎‡9 en-ca‏ ‎‡9 scn‏ ‎‡9 jam‏ ‎‡9 mg‏ ‎‡9 bar‏ ‎‡9 pt‏ ‎‡9 gsw‏ ‎‡9 sc‏ ‎‡9 fur‏ ‎‡9 mi‏ ‎‡9 sv‏ ‎‡9 de-ch‏ ‎‡9 frc‏ ‎‡9 sk‏ ‎‡9 pap‏ ‎‡9 oc‏ ‎‡9 ms‏ ‎‡9 de-at‏ ‎‡9 nds‏ ‎‡9 rgn‏ ‎‡9 pl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Philip C Robinson‏ ‎‡9 ast‏
400 0 ‎‡a ফিলিপ সি রবিনসন‏ ‎‡9 bn‏
400 0 ‎‡a Philip Robinson‏ ‎‡c New Zealand rheumatologist‏ ‎‡9 en‏
400 0 ‎‡a Philip C Robinson‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Philip Robinson‏ ‎‡c araştırmacı‏ ‎‡9 tr‏
670 ‎‡a Author's A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic‏
670 ‎‡a Author's A qualitative and quantitative analysis of the characteristics of gout patient education resources‏
670 ‎‡a Author's A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections‏
670 ‎‡a Author's Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment‏
670 ‎‡a Author's Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.‏
670 ‎‡a Author's Advances in pharmacotherapy for the treatment of gout‏
670 ‎‡a Author's Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials‏
670 ‎‡a Author's An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population‏
670 ‎‡a Author's Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital.‏
670 ‎‡a Author's Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin‏
670 ‎‡a Author's Author reply‏
670 ‎‡a Author's Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis‏
670 ‎‡a Author's Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19‏
670 ‎‡a Author's Biologic therapy for uveitis: addressing access issues is paramount‏
670 ‎‡a Author's Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis‏
670 ‎‡a Author's Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry‏
670 ‎‡a Author's Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis‏
670 ‎‡a Author's Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective‏
670 ‎‡a Author's Conducting research in a pandemic: The power of social media‏
670 ‎‡a Author's Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).‏
670 ‎‡a Author's Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand.‏
670 ‎‡a Author's Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation‏
670 ‎‡a Author's COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from‏
670 ‎‡a Author's COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations‏
670 ‎‡a Author's Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis‏
670 ‎‡a Author's Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis‏
670 ‎‡a Author's Does midlife obesity really lower dementia risk?‏
670 ‎‡a Author's Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis.‏
670 ‎‡a Author's Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases‏
670 ‎‡a Author's Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site‏
670 ‎‡a Author's ERAP1 biology and assessment in Ankylosing Spondylitis.‏
670 ‎‡a Author's ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers‏
670 ‎‡a Author's ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients‏
670 ‎‡a Author's Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study‏
670 ‎‡a Author's Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease‏
670 ‎‡a Author's Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry‏
670 ‎‡a Author's Febuxostat for the treatment of hyperuricaemia in gout‏
670 ‎‡a Author's Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist‏
670 ‎‡a Author's Genetic diagnostic profiling in axial spondyloarthritis: a real world study‏
670 ‎‡a Author's Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis‏
670 ‎‡a Author's Genetics of ankylosing spondylitis‏
670 ‎‡a Author's Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci‏
670 ‎‡a Author's Giant cell arteritis and COVID-19: similarities and discriminators, a systematic literature review‏
670 ‎‡a Author's Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance‏
670 ‎‡a Author's Gout - An update of aetiology, genetics, co-morbidities and management‏
670 ‎‡a Author's Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout‏
670 ‎‡a Author's Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout‏
670 ‎‡a Author's Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.‏
670 ‎‡a Author's Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank‏
670 ‎‡a Author's Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.‏
670 ‎‡a Author's Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci‏
670 ‎‡a Author's Insight into rheumatological cause and effect through the use of Mendelian randomization‏
670 ‎‡a Author's Lesinurad for the treatment of hyperuricaemia in people with gout‏
670 ‎‡a Author's Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.‏
670 ‎‡a Author's Management of autoimmune disease during the COVID-19 pandemic‏
670 ‎‡a Author's Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia‏
670 ‎‡a Author's Never too old for an inherited condition‏
670 ‎‡a Author's Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy‏
670 ‎‡a Author's Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes‏
670 ‎‡a Author's Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinic‏
670 ‎‡a Author's Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department‏
670 ‎‡a Author's Predictors of Success in Gout Treatment‏
670 ‎‡a Author's Race/ethnicity association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry‏
670 ‎‡a Author's Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al‏
670 ‎‡a Author's Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-repor‏
670 ‎‡a Author's Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries‏
670 ‎‡a Author's Role of genetics in infection-associated arthritis‏
670 ‎‡a Author's Rothia aeria as a cause of sepsis in a native joint‏
670 ‎‡a Author's SARS CoV-2 infection among patients using immunomodulatory therapies‏
670 ‎‡a Author's Severe hypothermia in association with sodium valproate overdose‏
670 ‎‡a Author's Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19‏
670 ‎‡a Author's Systematic review of the prevalence of gout and hyperuricaemia in Australia.‏
670 ‎‡a Author's The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward‏
670 ‎‡a Author's The Cost-effectiveness of Biannual Serum Urate‏
670 ‎‡a Author's The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring‏
670 ‎‡a Author's The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic‏
670 ‎‡a Author's The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice‏
670 ‎‡a Author's The effect of reducing systemic inflammation on serum urate‏
670 ‎‡a Author's The genetics of ankylosing spondylitis and axial spondyloarthritis‏
670 ‎‡a Author's The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis‏
670 ‎‡a Author's The management of gout: Much has changed‏
670 ‎‡a Author's The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19‏
670 ‎‡a Author's The prevalence of gout and hyperuricaemia in Australia: An updated systematic review‏
670 ‎‡a Author's The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance‏
670 ‎‡a Author's The window of opportunity: a relevant concept for axial spondyloarthritis‏
670 ‎‡a Author's Time to recognise gout as a chronic disease‏
670 ‎‡a Author's Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals‏
670 ‎‡a Author's Venous thromboembolism in medical inpatients--the silent epidemic of neglect‏
670 ‎‡a Author's Waiting for JAK inhibitor safety data‏
909 ‎‡a (orcid) 0000000231563418‏ ‎‡9 1‏
912 ‎‡a authorreply‏ ‎‡A Author reply‏ ‎‡9 1‏
912 ‎‡a gouthyperuricaemiaandcrystalassociateddiseasenetworkgcanconsensusstatementregardinglabelsanddefinitionsofdiseasestatesofgout‏ ‎‡A Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout‏ ‎‡9 1‏
912 ‎‡a identificationofmultipleriskvariantsforankylosingspondylitisthroughhighdensitygenotypingofimmunerelatedloci‏ ‎‡A Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci‏ ‎‡9 1‏
919 ‎‡a systematicreviewoftheinfectiouscomplicationsofcolchicineandtheuseofcolchicinetotreatinfections‏ ‎‡A A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections‏ ‎‡9 1‏
919 ‎‡a advancesinclassificationbasicmechanismsandclinicalscienceinankylosingspondylitisandaxialspondyloarthritis‏ ‎‡A Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.‏ ‎‡9 1‏
919 ‎‡a advancesinpharmacotherapyforthetreatmentofgout‏ ‎‡A Advances in pharmacotherapy for the treatment of gout‏ ‎‡9 1‏
919 ‎‡a adverseeventsduringoralcolchicineuseasystematicreviewandmetaanalysisofrandomisedcontrolledtrials‏ ‎‡A Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials‏ ‎‡9 1‏
919 ‎‡a observationalstudyofgoutprevalenceandqualityofcareinanationalaustraliangeneralpracticepopulation‏ ‎‡A An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population‏ ‎‡9 1‏
919 ‎‡a appropriatenessofantineutrophilcytoplasmicantibodytestinginatertiaryhospital‏ ‎‡A Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital.‏ ‎‡9 1‏
919 ‎‡a associationofcrohnsdiseaserelatedchromosome1q32withankylosingspondylitisisindependentofbowelsymptomsandfaecalcalprotectin‏ ‎‡A Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin‏ ‎‡9 1‏
919 ‎‡a axialspondyloarthritisanewdiseaseentitynotnecessarilyearlyankylosingspondylitis‏ ‎‡A Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis‏ ‎‡9 1‏
919 ‎‡a baselineuseofhydroxychloroquineinsystemiclupuserythematosusdoesnotprecludesarscov2infectionandseverecovid19‏ ‎‡A Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19‏ ‎‡9 1‏
919 ‎‡a biologictherapyforuveitisaddressingaccessissuesisparamount‏ ‎‡A Biologic therapy for uveitis: addressing access issues is paramount‏ ‎‡9 1‏
919 ‎‡a briefreportintestinaldysbiosisinankylosingspondylitis‏ ‎‡A Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis‏ ‎‡9 1‏
919 ‎‡a characteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianreportedregistry‏ ‎‡A Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry‏ ‎‡9 1‏
919 ‎‡a classificationcriteriaperipheralspondyloarthropathyandpsoriaticarthritis‏ ‎‡A Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis‏ ‎‡9 1‏
919 ‎‡a colchicineprophylaxisofgoutflareswhencommencingallopurinolisverycosteffective‏ ‎‡A Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective‏ ‎‡9 1‏
919 ‎‡a conductingresearchinapandemicthepowerofsocialmedia‏ ‎‡A Conducting research in a pandemic: The power of social media‏ ‎‡9 1‏
919 ‎‡a consensusstatementontheinvestigationandmanagementofnonradiographicaxialspondyloarthritisnraxspa‏ ‎‡A Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).‏ ‎‡9 1‏
919 ‎‡a consensusstatementsontheimagingofaxialspondyloarthritisinaustraliaandnewzealand‏ ‎‡A Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand.‏ ‎‡9 1‏
919 ‎‡a coronavirusdisease2019investigationaltherapiesinthepreventionandtreatmentofhyperinflammation‏ ‎‡A Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation‏ ‎‡9 1‏
919 ‎‡a covid19globalrheumatologyallianceregistryantiil6therapyshareddecisionmakingandpatientoutcomesresponsetocorrespondenceoncharacteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafrom‏ ‎‡A COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from‏ ‎‡9 1‏
919 ‎‡a covid19inpeoplewithrheumaticdiseasesrisksoutcomestreatmentconsiderations‏ ‎‡A COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations‏ ‎‡9 1‏
919 ‎‡a diffusionweightedimagingisasensitiveandspecificmagneticresonancesequenceinthediagnosisofankylosingspondylitis‏ ‎‡A Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis‏ ‎‡9 1‏
919 ‎‡a diseaseassociatedpolymorphismsinerap1donotalterendoplasmicreticulumstressinpatientswithankylosingspondylitis‏ ‎‡A Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis‏ ‎‡9 1‏
919 ‎‡a doesmidlifeobesityreallylowerdementiarisk‏ ‎‡A Does midlife obesity really lower dementia risk?‏ ‎‡9 1‏
919 ‎‡a endoplasmicreticulumaminopeptidasesinthepathogenesisofankylosingspondylitis‏ ‎‡A Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis.‏ ‎‡9 1‏
919 ‎‡a epidemiologyandoutcomesofnovelcoronavirus2019inpatientswithimmunemediatedinflammatorydiseases‏ ‎‡A Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases‏ ‎‡9 1‏
919 ‎‡a epidemiologyofinpatientgoutinaustraliaandnewzealandtemporaltrendscomorbiditiesandgoutflaresite‏ ‎‡A Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site‏ ‎‡9 1‏
919 ‎‡a erap1biologyandassessmentinankylosingspondylitis‏ ‎‡A ERAP1 biology and assessment in Ankylosing Spondylitis.‏ ‎‡9 1‏
919 ‎‡a erap2functionalknockoutinhumansdoesnotaltersurfaceheavychainsorhlab27inflammatorycytokinesorendoplasmicreticulumstressmarkers‏ ‎‡A ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers‏ ‎‡9 1‏
919 ‎‡a erap2isassociatedwithankylosingspondylitisinhlab27positiveandhlab27negativepatients‏ ‎‡A ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients‏ ‎‡9 1‏
919 ‎‡a evaluationoftheeffectofbaselinemrisacroiliitisand100reactiveproteinstatusonetanercepttreatmentresponseinnonradiographicaxialspondyloarthritisaposthocanalysisoftheembarkstudy‏ ‎‡A Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study‏ ‎‡9 1‏
919 ‎‡a exomewidestudyofankylosingspondylitisdemonstratesadditionalsharedgeneticbackgroundwithinflammatoryboweldisease‏ ‎‡A Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease‏ ‎‡9 1‏
919 ‎‡a factorsassociatedwithcovid19relateddeathinpeoplewithrheumaticdiseasesresultsfromthecovid19globalrheumatologyalliancephysicianreportedregistry‏ ‎‡A Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry‏ ‎‡9 1‏
919 ‎‡a febuxostatforthetreatmentofhyperuricaemiaingout‏ ‎‡A Febuxostat for the treatment of hyperuricaemia in gout‏ ‎‡9 1‏
919 ‎‡a festinalentehydroxychloroquinecovid19andtheroleoftherheumatologist‏ ‎‡A Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist‏ ‎‡9 1‏
919 ‎‡a geneticdiagnosticprofilinginaxialspondyloarthritisarealworldstudy‏ ‎‡A Genetic diagnostic profiling in axial spondyloarthritis: a real world study‏ ‎‡9 1‏
919 ‎‡a geneticdissectionofacuteanterioruveitisrevealssimilaritiesanddifferencesinassociationsobservedwithankylosingspondylitis‏ ‎‡A Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis‏ ‎‡9 1‏
919 ‎‡a geneticsofankylosingspondylitis‏ ‎‡A Genetics of ankylosing spondylitis‏ ‎‡9 1‏
919 ‎‡a genomewideassociationstudyofacuteanterioruveitisidentifiesnewsusceptibilityloci‏ ‎‡A Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci‏ ‎‡9 1‏
919 ‎‡a giantcellarteritisandcovid19similaritiesanddiscriminatorsasystematicliteraturereview‏ ‎‡A Giant cell arteritis and COVID-19: similarities and discriminators, a systematic literature review‏ ‎‡9 1‏
919 ‎‡a globalresearchcollaborationinapandemicchallengesandopportunitiesthecovid19globalrheumatologyalliance‏ ‎‡A Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance‏ ‎‡9 1‏
919 ‎‡a goutanupdateofaetiologygeneticscomorbiditiesandmanagement‏ ‎‡A Gout - An update of aetiology, genetics, co-morbidities and management‏ ‎‡9 1‏
919 ‎‡a gouthyperuricemiaandcrystalassociateddiseasenetworkconsensusstatementregardinglabelsanddefinitionsfordiseaseelementsingout‏ ‎‡A Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout‏ ‎‡9 1‏
919 ‎‡a goutjointsandbeyondepidemiologyclinicalfeaturestreatmentandcomorbidities‏ ‎‡A Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.‏ ‎‡9 1‏
919 ‎‡a goutrheumatoidarthritisandtheriskofdeathrelatedtocoronavirusdisease2019ananalysisoftheukbiobank‏ ‎‡A Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank‏ ‎‡9 1‏
919 ‎‡a hospitaladmissionsassociatedwithgoutandtheircomorbiditiesinnewzealandandengland1999‏ ‎‡A Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.‏ ‎‡9 1‏
919 ‎‡a insightintorheumatologicalcauseandeffectthroughtheuseofmendelianrandomization‏ ‎‡A Insight into rheumatological cause and effect through the use of Mendelian randomization‏ ‎‡9 1‏
919 ‎‡a lesinuradforthetreatmentofhyperuricaemiainpeoplewithgout‏ ‎‡A Lesinurad for the treatment of hyperuricaemia in people with gout‏ ‎‡9 1‏
919 ‎‡a majorhistocompatibilitycomplexassociationsofankylosingspondylitisarecomplexandinvolvefurtherepistasiswitherap1‏ ‎‡A Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.‏ ‎‡9 1‏
919 ‎‡a managementofautoimmunediseaseduringthecovid19pandemic‏ ‎‡A Management of autoimmune disease during the COVID-19 pandemic‏ ‎‡9 1‏
919 ‎‡a managementofpatientswithgoutandachievementoftargetserumuratelevelsatatertiaryrheumatologyserviceinaustralia‏ ‎‡A Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia‏ ‎‡9 1‏
919 ‎‡a nevertoooldforaninheritedcondition‏ ‎‡A Never too old for an inherited condition‏ ‎‡9 1‏
919 ‎‡a nonradiographicaxialspondyloarthritisnraxspaadvancesinclassificationimagingandtherapy‏ ‎‡A Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy‏ ‎‡9 1‏
919 ‎‡a novelcoronavirusdisease2019covid19inpeoplewithrheumaticdiseaseepidemiologyandoutcomes‏ ‎‡A Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes‏ ‎‡9 1‏
919 ‎‡a patientswithsystemiclupuserythematosususinghydroxychloroquineorchloroquinedevelopseverecovid19atsimilarfrequencyaspatientsnotonantimalarialsneedtoexploreantithromboticbenefitsforcovid19coagulopathyresponsetoclinic‏ ‎‡A Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinic‏ ‎‡9 1‏
919 ‎‡a poorcompliancewithcommunityacquiredpneumoniaantibioticguidelinesinalargeaustralianprivatehospitalemergencydepartment‏ ‎‡A Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department‏ ‎‡9 1‏
919 ‎‡a predictorsofsuccessingouttreatment‏ ‎‡A Predictors of Success in Gout Treatment‏ ‎‡9 1‏
919 ‎‡a raceethnicityassociationwithcovid19outcomesinrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianregistry‏ ‎‡A Race/ethnicity association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry‏ ‎‡9 1‏
919 ‎‡a responsetoglucocorticoidinducedrelapseofcovid19inapatientwithsarcoidosisbygyorfietal‏ ‎‡A Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al‏ ‎‡9 1‏
919 ‎‡a rheumaticdiseaseactivityglucocorticoiduseandcovid19responsetocommentoncharacteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianrepor‏ ‎‡A Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-repor‏ ‎‡9 1‏
919 ‎‡a rheumaticdiseaseandcovid19initialdatafromthecovid19globalrheumatologyallianceproviderregistries‏ ‎‡A Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries‏ ‎‡9 1‏
919 ‎‡a roleofgeneticsininfectionassociatedarthritis‏ ‎‡A Role of genetics in infection-associated arthritis‏ ‎‡9 1‏
919 ‎‡a rothiaaeriaasacauseofsepsisinanativejoint‏ ‎‡A Rothia aeria as a cause of sepsis in a native joint‏ ‎‡9 1‏
919 ‎‡a sarscov2infectionamongpatientsusingimmunomodulatorytherapies‏ ‎‡A SARS CoV-2 infection among patients using immunomodulatory therapies‏ ‎‡9 1‏
919 ‎‡a severehypothermiainassociationwithsodiumvalproateoverdose‏ ‎‡A Severe hypothermia in association with sodium valproate overdose‏ ‎‡9 1‏
919 ‎‡a swingingthependulumlessonslearnedfrompublicdiscourseconcerninghydroxychloroquineandcovid19‏ ‎‡A Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19‏ ‎‡9 1‏
919 ‎‡a systematicreviewoftheprevalenceofgoutandhyperuricaemiainaustralia‏ ‎‡A Systematic review of the prevalence of gout and hyperuricaemia in Australia.‏ ‎‡9 1‏
919 ‎‡a asascriteriaforaxialspondyloarthritisstrengthsweaknessesandproposalsforawayforward‏ ‎‡A The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofbiannualserumurate‏ ‎‡A The Cost-effectiveness of Biannual Serum Urate‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofbiannualserumuratesumonitoringafterreachingtargetingoutahealtheconomicanalysiscomparingsumonitoring‏ ‎‡A The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring‏ ‎‡9 1‏
919 ‎‡a covid19globalrheumatologyalliancecollectingdatainapandemic‏ ‎‡A The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic‏ ‎‡9 1‏
919 ‎‡a covid19globalrheumatologyallianceevaluatingtherapiddesignandimplementationofaninternationalregistryagainstbestpractice‏ ‎‡A The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice‏ ‎‡9 1‏
919 ‎‡a effectofreducingsystemicinflammationonserumurate‏ ‎‡A The effect of reducing systemic inflammation on serum urate‏ ‎‡9 1‏
919 ‎‡a geneticsofankylosingspondylitisandaxialspondyloarthritis‏ ‎‡A The genetics of ankylosing spondylitis and axial spondyloarthritis‏ ‎‡9 1‏
919 ‎‡a intestinalmicrobiomeinhumandiseaseandhowitrelatestoarthritisandspondyloarthritis‏ ‎‡A The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis‏ ‎‡9 1‏
919 ‎‡a managementofgoutmuchhaschanged‏ ‎‡A The management of gout: Much has changed‏ ‎‡9 1‏
919 ‎‡a potentialforrepurposingantitnfasatherapyforthetreatmentofcovid19‏ ‎‡A The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19‏ ‎‡9 1‏
919 ‎‡a prevalenceofgoutandhyperuricaemiainaustraliaanupdatedsystematicreview‏ ‎‡A The prevalence of gout and hyperuricaemia in Australia: An updated systematic review‏ ‎‡9 1‏
919 ‎‡a rheumatologycommunityrespondstothecovid19pandemictheestablishmentofthecovid19globalrheumatologyalliance‏ ‎‡A The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance‏ ‎‡9 1‏
919 ‎‡a windowofopportunityarelevantconceptforaxialspondyloarthritis‏ ‎‡A The window of opportunity: a relevant concept for axial spondyloarthritis‏ ‎‡9 1‏
919 ‎‡a timetorecognisegoutasachronicdisease‏ ‎‡A Time to recognise gout as a chronic disease‏ ‎‡9 1‏
919 ‎‡a timetotreatmentinrheumatoidarthritisfactorsassociatedwithtimetotreatmentinitiationandurgenttriageassessmentofgeneralpractitionerreferrals‏ ‎‡A Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals‏ ‎‡9 1‏
919 ‎‡a venousthromboembolisminmedicalinpatientsthesilentepidemicofneglect‏ ‎‡A Venous thromboembolism in medical inpatients--the silent epidemic of neglect‏ ‎‡9 1‏
919 ‎‡a waitingforjakinhibitorsafetydata‏ ‎‡A Waiting for JAK inhibitor safety data‏ ‎‡9 1‏
919 ‎‡a accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment‏ ‎‡A Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsinformedapproachtonavigatinghydroxychloroquineshortagesinpatientswithrheumaticdiseaseduringthecovid19pandemic‏ ‎‡A A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic‏ ‎‡9 1‏
919 ‎‡a qualitativeandquantitativeanalysisofthecharacteristicsofgoutpatienteducationresources‏ ‎‡A A qualitative and quantitative analysis of the characteristics of gout patient education resources‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2009‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000387041843‏
996 ‎‡2 SIMACOB|22906979‏
996 ‎‡2 PLWABN|9810670480405606‏
996 ‎‡2 BIBSYS|90685671‏
996 ‎‡2 BIBSYS|12046540‏
996 ‎‡2 ISNI|0000000395392707‏
996 ‎‡2 J9U|987007424725505171‏
996 ‎‡2 BNC|981058609025406706‏
996 ‎‡2 SIMACOB|7219811‏
996 ‎‡2 BIBSYS|90920247‏
996 ‎‡2 LC|no 99022121‏
996 ‎‡2 DBC|87097948918417‏
996 ‎‡2 BNF|14132645‏
996 ‎‡2 ISNI|0000000030966253‏
996 ‎‡2 LC|n 2010185059‏
996 ‎‡2 ISNI|0000000028706807‏
996 ‎‡2 LC|n 89672291‏
996 ‎‡2 BNF|12498886‏
996 ‎‡2 RERO|A011484104‏
996 ‎‡2 BIBSYS|90393357‏
996 ‎‡2 SUDOC|111716314‏
996 ‎‡2 DBC|87097969668194‏
996 ‎‡2 BIBSYS|90268423‏
996 ‎‡2 N6I|vtls001380620‏
996 ‎‡2 LC|no2011090638‏
996 ‎‡2 ISNI|0000000067244289‏
996 ‎‡2 NII|DA03788112‏
996 ‎‡2 LC|n 84028876‏
996 ‎‡2 NKC|xx0201986‏
996 ‎‡2 NTA|24297841X‏
996 ‎‡2 BNF|12500126‏
996 ‎‡2 DNB|1078141444‏
996 ‎‡2 NDL|00744776‏
996 ‎‡2 NTA|072425563‏
996 ‎‡2 J9U|987007436558905171‏
996 ‎‡2 ISNI|0000000109593277‏
996 ‎‡2 DNB|141930241‏
996 ‎‡2 BNF|13072683‏
996 ‎‡2 LC|no2008130075‏
996 ‎‡2 SUDOC|257796770‏
996 ‎‡2 ISNI|0000000433802253‏
996 ‎‡2 J9U|987007449410705171‏
996 ‎‡2 ISNI|0000000081691077‏
996 ‎‡2 RERO|A009361512‏
996 ‎‡2 LIH|LNB:BE_i__g_;=B_n_‏
996 ‎‡2 NUKAT|n 98007492‏
996 ‎‡2 ISNI|000000012277243X‏
996 ‎‡2 J9U|987007281045705171‏
996 ‎‡2 DBC|87097969668208‏
996 ‎‡2 DNB|122216946‏
996 ‎‡2 BNE|XX1596941‏
996 ‎‡2 NTA|068283520‏
996 ‎‡2 NTA|068217749‏
996 ‎‡2 RERO|A003752233‏
996 ‎‡2 DNB|1157227031‏
996 ‎‡2 SUDOC|095159304‏
996 ‎‡2 NLA|000035457257‏
996 ‎‡2 DNB|129577243‏
996 ‎‡2 LC|no 96027255‏
996 ‎‡2 LC|nb2011015484‏
996 ‎‡2 LC|n 89621570‏
996 ‎‡2 BIBSYS|90107897‏
996 ‎‡2 ISNI|0000000039443299‏
996 ‎‡2 SUDOC|171183495‏
996 ‎‡2 ISNI|0000000421093939‏
996 ‎‡2 LC|n 2012069387‏
996 ‎‡2 LC|no2016044946‏
996 ‎‡2 BIBSYS|90563567‏
996 ‎‡2 NUKAT|n 98085257‏
996 ‎‡2 SZ|122216946‏
996 ‎‡2 ISNI|0000000499934267‏
996 ‎‡2 CAOONL|ncf11585405‏
996 ‎‡2 LC|no2018172862‏
996 ‎‡2 PTBNP|1075323‏
996 ‎‡2 PLWABN|9810590929405606‏
996 ‎‡2 BNF|15071814‏
996 ‎‡2 NKC|mub2013766629‏
996 ‎‡2 CAOONL|ncf10083939‏
996 ‎‡2 NLA|000036004296‏
996 ‎‡2 NII|DA0821577X‏
996 ‎‡2 LC|nb2002064415‏
996 ‎‡2 BIBSYS|90945226‏
996 ‎‡2 LC|n 83208325‏
996 ‎‡2 NTA|283600128‏
996 ‎‡2 NTA|073432520‏
996 ‎‡2 NUKAT|n 2005018713‏
996 ‎‡2 LC|nb2016021802‏
996 ‎‡2 SUDOC|119356945‏
996 ‎‡2 SIMACOB|418840835‏
996 ‎‡2 BIBSYS|90652323‏
996 ‎‡2 BIBSYS|90185694‏
996 ‎‡2 DNB|122218248‏
996 ‎‡2 J9U|987007350857105171‏
996 ‎‡2 BNF|15798320‏
996 ‎‡2 RERO|A024299684‏
996 ‎‡2 NTA|072091479‏
996 ‎‡2 DNB|1193151384‏
996 ‎‡2 J9U|987007267157405171‏
996 ‎‡2 ISNI|0000000024316668‏
996 ‎‡2 BIBSYS|98039773‏
996 ‎‡2 LC|nb2023015504‏
996 ‎‡2 DE633|pe30028786‏
996 ‎‡2 NII|DA10164117‏
996 ‎‡2 LNB|LNC10-000145728‏
996 ‎‡2 NUKAT|n 2016005147‏
996 ‎‡2 LC|no2008167742‏
996 ‎‡2 SUDOC|034208844‏
996 ‎‡2 LC|no2009077612‏
996 ‎‡2 NII|DA06391421‏
996 ‎‡2 BNE|XX1005540‏
996 ‎‡2 SUDOC|248214306‏
996 ‎‡2 SUDOC|23780381X‏
996 ‎‡2 ISNI|0000000114196719‏
996 ‎‡2 SUDOC|257615709‏
996 ‎‡2 LC|nb2008000818‏
996 ‎‡2 ISNI|0000000383052705‏
996 ‎‡2 SUDOC|16221250X‏
996 ‎‡2 BNC|981058514131506706‏
996 ‎‡2 ISNI|0000000120474316‏
996 ‎‡2 LNB|LNC10-000033723‏
996 ‎‡2 NII|DA00828968‏
996 ‎‡2 SUDOC|24078314X‏
996 ‎‡2 ISNI|0000000060137245‏
996 ‎‡2 SUDOC|167705318‏
996 ‎‡2 LC|nb2019000596‏
996 ‎‡2 LC|n 91063924‏
996 ‎‡2 J9U|987007458311905171‏
996 ‎‡2 DNB|1165157950‏
996 ‎‡2 ISNI|0000000453516377‏
996 ‎‡2 SIMACOB|16593763‏
996 ‎‡2 BNF|16945031‏
996 ‎‡2 BNE|XX978993‏
996 ‎‡2 ISNI|0000000121397754‏
996 ‎‡2 NTA|071947930‏
996 ‎‡2 ISNI|000000004347360X‏
996 ‎‡2 RERO|A012381098‏
996 ‎‡2 N6I|vtls001339002‏
996 ‎‡2 DNB|1146270356‏
996 ‎‡2 CAOONL|ncf11173551‏
996 ‎‡2 LC|n 81134909‏
996 ‎‡2 J9U|987007447078505171‏
996 ‎‡2 BIBSYS|90093057‏
996 ‎‡2 SUDOC|139421211‏
996 ‎‡2 LC|no2003100051‏
996 ‎‡2 LC|n 89638386‏
996 ‎‡2 NII|DA05533597‏
996 ‎‡2 BIBSYS|90503076‏
996 ‎‡2 SIMACOB|161784419‏
996 ‎‡2 ISNI|0000000054131162‏
996 ‎‡2 SUDOC|081069677‏
996 ‎‡2 SIMACOB|229047139‏
996 ‎‡2 LC|n 88056718‏
996 ‎‡2 ISNI|0000000106775016‏
996 ‎‡2 ISNI|000000043493643X‏
996 ‎‡2 LC|no2019169642‏
996 ‎‡2 RERO|A003752235‏
996 ‎‡2 RERO|A012332750‏
996 ‎‡2 RERO|A025500390‏
996 ‎‡2 NDL|00956843‏
996 ‎‡2 RERO|A010141671‏
996 ‎‡2 NII|DA03814234‏
996 ‎‡2 LC|no2015012247‏
996 ‎‡2 ISNI|0000000496479975‏
996 ‎‡2 SIMACOB|418849027‏
996 ‎‡2 CAOONL|ncf10134451‏
996 ‎‡2 LC|no 95058483‏
996 ‎‡2 SZ|1165157950‏
996 ‎‡2 ISNI|0000000398683198‏
996 ‎‡2 ISNI|0000000110578015‏
996 ‎‡2 BIBSYS|90268848‏
996 ‎‡2 ISNI|0000000425497842‏
996 ‎‡2 LC|nb2011019978‏
996 ‎‡2 NYNYRILM|175703‏
996 ‎‡2 NUKAT|n 2020210662‏
996 ‎‡2 LC|n 96065043‏
996 ‎‡2 LC|no2022114969‏
996 ‎‡2 SUDOC|167726927‏
996 ‎‡2 LC|n 92027545‏
996 ‎‡2 BIBSYS|1054071‏
996 ‎‡2 NUKAT|n 2019157649‏
996 ‎‡2 ISNI|0000000050867930‏
996 ‎‡2 PTBNP|231789‏
996 ‎‡2 NUKAT|n 2016084279‏
996 ‎‡2 BNE|XX4934829‏
996 ‎‡2 NTA|074525689‏
996 ‎‡2 LC|n 90690308‏
996 ‎‡2 LC|n 84217486‏
996 ‎‡2 J9U|987007456527105171‏
996 ‎‡2 BNF|15595696‏
996 ‎‡2 SIMACOB|299486051‏
996 ‎‡2 LC|n 88184392‏
996 ‎‡2 LC|nb2005014799‏
996 ‎‡2 LC|n 2014020261‏
996 ‎‡2 ISNI|0000000023570445‏
996 ‎‡2 ISNI|000000010999912X‏
996 ‎‡2 BIBSYS|90116051‏
996 ‎‡2 LC|no 99022107‏
996 ‎‡2 ISNI|0000000108218942‏
996 ‎‡2 SIMACOB|100024419‏
996 ‎‡2 ISNI|0000000041267239‏
996 ‎‡2 ISNI|0000000108586614‏
996 ‎‡2 RERO|A003752217‏
996 ‎‡2 SUDOC|188177728‏
996 ‎‡2 RERO|A021517853‏
996 ‎‡2 PLWABN|9810695779605606‏
996 ‎‡2 J9U|987007350722405171‏
996 ‎‡2 J9U|987007361869605171‏
996 ‎‡2 LC|nb 97066186‏
996 ‎‡2 NSK|000103522‏
996 ‎‡2 DNB|12221837X‏
996 ‎‡2 SUDOC|255366779‏
996 ‎‡2 SUDOC|254339077‏
996 ‎‡2 LC|n 81095592‏
996 ‎‡2 BIBSYS|90132221‏
996 ‎‡2 ISNI|0000000037025667‏
996 ‎‡2 NKC|xx0040136‏
996 ‎‡2 ISNI|0000000120452790‏
996 ‎‡2 ISNI|0000000078258125‏
996 ‎‡2 NII|DA07003302‏
996 ‎‡2 LC|n 2004002915‏
996 ‎‡2 BLBNB|000334852‏
996 ‎‡2 NTA|071776710‏
996 ‎‡2 BLBNB|000334856‏
996 ‎‡2 BIBSYS|90239843‏
996 ‎‡2 LC|n 83229391‏
996 ‎‡2 N6I|vtls000042579‏
996 ‎‡2 BIBSYS|90630075‏
996 ‎‡2 J9U|987007373539105171‏
996 ‎‡2 LC|nb2003022262‏
996 ‎‡2 SUDOC|069511748‏
996 ‎‡2 SUDOC|078680913‏
996 ‎‡2 DNB|1341102440‏
996 ‎‡2 LC|n 81134908‏
996 ‎‡2 CAOONL|ncf11327372‏
996 ‎‡2 ISNI|000000003929406X‏
996 ‎‡2 SUDOC|270794107‏
996 ‎‡2 NII|DA13775525‏
996 ‎‡2 PLWABN|9810544269105606‏
996 ‎‡2 DNB|1136632131‏
996 ‎‡2 ISNI|0000000053567060‏
996 ‎‡2 BAV|495_373499‏
996 ‎‡2 NTA|315485310‏
996 ‎‡2 NKC|xx0114041‏
996 ‎‡2 DNB|122223888‏
996 ‎‡2 SUDOC|261205544‏
996 ‎‡2 BIBSYS|12053921‏
996 ‎‡2 NII|DA19248522‏
996 ‎‡2 RERO|A021510948‏
996 ‎‡2 NUKAT|n 93081272‏
996 ‎‡2 LIH|LNB:B9U_a_;=BX‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Robinson, Philip‏ ‎‡2 ISNI|0000000110578015‏ ‎‡3 exact name‏
998 ‎‡a Robinson, Philip‏ ‎‡2 ISNI|0000000110578015‏ ‎‡3 exact name‏
998 ‎‡a Philip Robinson‏ ‎‡2 ISNI|0000000110578015‏ ‎‡3 exact name‏